NCT04115878View on ClinicalTrials.gov

Medications for Obstructive Sleep Apnea In Children With Down Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 21, 2020

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2022

Conditions
Obstructive Sleep ApneaDown Syndrome
Interventions
DRUG

Atomoxetine and oxybutynin (ato-oxy)

Low dose ato-oxy will include 0.5 mg/kg/day of atomoxetine (max 40 mg) in combination with 5 mg oxybutynin High dose ato-oxy will include 1.2 mg/kg/day atomoxetine (max 80 mg) and 5 mg oxybutynin

Trial Locations (1)

85721

University of Arizona, Tucson

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Arizona

OTHER

NCT04115878 - Medications for Obstructive Sleep Apnea In Children With Down Syndrome | Biotech Hunter | Biotech Hunter